Product image of Nimotop (Nimodipine) supplied by GNH India

Nimotop

Active Ingredient:
Nimodipine
Origin:
EU

Nimotop (Nimodipine)

Nimodipine, the active ingredient in Nimotop, is a calcium channel blocker presented as an injectable solution for intravenous use. It is employed to prevent cerebral vasospasm that can occur after subarachnoid hemorrhage, helping to maintain adequate blood flow to the brain in affected patients. By selectively antagonizing L‑type calcium channels in cerebral arteries, nimodipine reduces calcium influx and relaxes vascular smooth muscle, thereby mitigating the risk of vessel narrowing.

GNH India supplies Nimotop as a licensed, GDP‑compliant international pharmaceutical product to hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Bayer Plc

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Nimotop acts on the cerebral vascular system to prevent complications after subarachnoid hemorrhage.

  • Cerebral vasospasm after subarachnoid hemorrhage: reduces the incidence and severity of vessel narrowing.
  • Delayed ischemic neurological deficits after SAH: helps maintain cerebral perfusion and limits neurological decline.
  • Neuroprotection in acute brain injury: provides calcium‑channel mediated protection of neuronal tissue.

How It Works

  • Nimodipine selectively blocks L‑type calcium channels on vascular smooth muscle, especially in cerebral arteries. This inhibition decreases calcium entry into the cells, leading to relaxation of the arterial wall, prevention of vasospasm, and improved cerebral blood flow. The drug’s preferential action on cerebral vessels underlies its neuroprotective properties in the setting of subarachnoid hemorrhage.

Side Effects

Nimotop may be associated with a range of adverse reactions.

Common Side Effects

  • Headache: mild to moderate intensity.
  • Hypotension: transient drop in blood pressure.
  • Nausea or vomiting: gastrointestinal discomfort.
  • Flushing: warm sensation and reddening of skin.

Serious or Rare Side Effects

  • Severe hypotension: may require medical intervention.
  • Cardiac arrhythmias: irregular heart rhythm.
  • Allergic reactions: rash, itching, or anaphylaxis.
  • Liver enzyme elevation: abnormal hepatic function tests.

Precautions & Warnings

Before using Nimotop, consider the following safety measures.

  • Blood pressure monitoring: assess baseline and periodic readings.
  • Cardiac assessment: evaluate for existing arrhythmias or heart disease.
  • Liver function: check hepatic enzymes prior to initiation.
  • Concomitant vasodilators: avoid additive hypotensive effects.
  • Pregnancy and lactation: use only if the potential benefit justifies the risk.
  • Store below 25°C: keep in the original container, protect from light and moisture.

Avoid Interactions

Nimotop can interact with several medicines; awareness of the interaction level is essential.

Major Interactions (Avoid)

  • Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase nimodipine plasma levels.
  • Other potent vasodilators (e.g., nitroglycerin): risk of severe hypotension.

Moderate Interactions (Monitor Closely):\n- CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce efficacy.

  • Beta‑blockers: additive effects on heart rate and blood pressure.
  • Diuretics: monitor electrolytes and volume status.

Frequently Asked Questions

Nimotop is an intravenous formulation of nimodipine that is used to prevent cerebral vasospasm following a subarachnoid hemorrhage. By keeping the brain’s blood vessels dilated, it helps maintain adequate cerebral perfusion and reduces the risk of delayed ischemic neurological deficits.

Nimodipine selectively blocks L‑type calcium channels on the smooth muscle of cerebral arteries. This action limits calcium entry, causing the vessels to relax and preventing the narrowing (vasospasm) that can occur after bleeding into the subarachnoid space.

The dosage of Nimotop is determined by the prescribing clinician based on the patient’s condition, weight, and response. Healthcare professionals set the appropriate infusion rate and duration according to established clinical guidelines.

Safety data for Nimotop in pregnancy and lactation are limited. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To request Nimotop, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Nimotop (nimodipine) is distinguished by its high affinity for cerebral vessels, making it especially effective for preventing vasospasm after subarachnoid hemorrhage. Other dihydropyridine blockers, such as amlodipine, are primarily used for systemic hypertension and lack the same degree of neurovascular selectivity.

Nimotop should be stored below 25 °C in its original packaging, protected from light and moisture. The solution must be kept in a controlled environment and inspected for particulate matter before administration.

Nimotop is given by intravenous infusion under the supervision of a qualified healthcare professional. The infusion rate and duration are set according to the patient’s clinical status and institutional protocols.

The most serious risks include severe hypotension, which can lead to shock, and cardiac arrhythmias. Rarely, patients may experience allergic reactions such as anaphylaxis. Prompt monitoring of blood pressure and cardiac rhythm is essential during treatment.

Nimotop is contraindicated in patients with known hypersensitivity to nimodipine or any component of the formulation, and in those with uncontrolled severe hypotension. Caution is also advised for individuals taking strong CYP3A4 inhibitors or other potent vasodilators.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Nimodipine

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT